Avidity Biosciences Inc is a biotechnology company that focuses on developing therapies using its proprietary AOC (Antibody Oligonucleotide Conjugate) platform. The company's AOC technology combines the targeting specificity of antibodies with the therapeutic potential of oligonucleotide-based therapies to create novel and highly selective treatments for various diseases.
Avidity Biosciences was founded in 2012 by Dr. Troy Wilson and Dr. Kent Hawryluk, with the aim of advancing precision medicine by leveraging the power of oligonucleotide therapeutics. The company is headquartered in La Jolla, California.
The core principle behind Avidity's AOC platform is to enhance the delivery and targeting of oligonucleotides to specific cells or tissues using monoclonal antibodies as vehicles. By precisely delivering therapeutic oligonucleotides to the intended sites, Avidity aims to improve the effectiveness and safety of these therapies for patients.
Avidity's pipeline includes a diverse range of programs targeting genetic disorders, neurodegenerative diseases, and other serious medical conditions. One of its lead drug candidates is focused on addressing myotonic dystrophy type 1 (DM1), a rare and debilitating genetic disorder.
The company's scientific expertise, combined with strategic partnerships and collaborations with leading academic institutions and biopharmaceutical companies, has allowed Avidity to accelerate its drug discovery and development efforts. These partnerships offer access to cutting-edge technologies and additional resources to further advance the development of its therapeutic candidates.
Avidity's commitment to advancing precision medicine and developing innovative therapies using its unique AOC platform has positioned it as a key player in the biotechnology industry. The company continues to focus on advancing its pipeline and exploring new therapeutic opportunities, with the ultimate goal of improving patients' lives through targeted and effective treatments.